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Background
At the very end of 2019 the Chinese Center for Disease Control (China CDC) reported 
several severe pneumonia cases of unknown etiology in the city of Wuhan. The causative 
agent of the disease was a previously unknown Betacoronavirus named SARS-CoV-2. 
The virus quickly spread all over the globe (https:// www. who. int/ emerg encies/ disea ses/ 
novel- coron avirus- 2019; https:// www. world omete rs. info/ coron avirus/) and as of today 
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(June 2020) the number of infections and the number of deaths were globally still on the 
rise.
Coronaviruses are widespread in vertebrates and cause a plethora of respiratory, 
enteric, hepatic, and neurologic issues. Some of the animal coronaviruses exhibited abil-
ity to transmit to human e.g. the severe acute respiratory syndrome coronavirus (SARS-
CoV) in 2003 and Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012 
had caused human epidemics [1, 2]. SARS-CoVs enters cells via the angiotensin-convert-
ing enzyme 2 (ACE2) receptor [3, 4]. The SARS-CoV-2 first infects airways and binds 
to ACE2 on alveolar epithelial cells. Both viruses are potent inducers of inflammatory 
cytokines [5]. The virus activates immune cells and induces the secretion of inflamma-
tory cytokines and chemokines into pulmonary vascular endothelial cells. In severe cases 
of COVID-19 the patient develops a “cytokine storm” [6–9]. Since most infected individ-
uals are apparently asymptomatic it is hard to assess the prevalence of SARS-CoV-2 in 
global or even local populations. Lack of appropriate testing quantities also plays a role. 
To date there are no fully effective drugs or vaccines against SARS-CoV-2 [6, 10–14].
Several recent articles have suggested that SARS-CoV-2 proteins and some protein 
domains are important to the viral lifecycle, several of which are conserved in the Coro-
naviridae family and which are possible targets as epitopes [15–22]. This is of impor-
tance since the choice of proper target/epitopes is crucial for drug or vaccine design.
The quest for optimal epitope targets is difficult and focuses on both experimental 
and bioinformatic means. This may directly involve laboratory experiments or databases 
like the Immune Epitope Database and Analysis Resource (IEDB)[16, 22, 23]. The sec-
ond bioinformatic approach uses the search for similarities with other viruses in order to 
identify conserved regions of the viral genome [19, 24, 25].
Although both methods focus on the viral RNA/proteome sequence, these approaches 
clearly treat this sequence as a whole. However, one can clearly distinguish between pro-
tein high complexity regions (HCRs) encompassing most of the genome and low com-
plexity regions (LCRs). LCRs are often described as ‘unstructured’ or are simply not 
annotated. Our recent experiments however show that the search for similar sequences 
in LCRs is almost impossible using standard methods, like BLAST or HHblits [26, 27]. 
This is why we created three algorithms that are able to compare low complexity protein 
sequences, GBSC, MotifLCR and LCR-BLAST [28–32].
The current situation due to COVID-19 is critical, and this work aims to compare the 
SARS-CoV-2 LCRs with the human proteome. In this work we show that numerous 
fragments of the viral proteome are very similar to the human ones. It has been recently 
shown that the furin cleavage site of Spike SARS-CoV-2 protein shares similarity with 
the human epithelial sodium channel [33]. Our findings suggest that identified frag-
ments of spike, nsp3 and nucleocapsid proteins should not be considered as epitopes 
neither for vaccine nor drug design.
Moreover, our hypothesis is supported by the malaria molecular evolution and vaccine 
design study clearly indicating that LCRs may play a role in immune escape mechanism 
[34]. The attempt to develop about 100 anti-malaria vaccine candidates indicated their 
limited protective effect. The global analysis of antigens led to the conclusion that LCRs 
present in proteins containing glutamate-rich and/or repetitive motifs carried the most 
immunogenic epitopes. On the other hand the antibodies recognizing these epitopes 
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appeared to be ineffective in an in  vitro study [35]. Moreover, the exhaustive study 
showed that LCRs may drive the immune response away from important functional 
domains in parasite proteins [35]. In this context it seems to be very important to avoid 
the presence of LCRs in vaccine epitopes due to 1) low effectiveness of antibodies rec-
ognizing this region, even if LCRs are highly immunogenic and 2) the presence of LCRs 
in some human proteins. Additionally, the deep study revealed that molecular mimicry 
may serve as an attractive explanation of autoimmune side effects after pathogen infec-
tions [36]. Moreover, it was already reported in COVID-19 that some patients developed 
the self-reacting antibody like e.g. anti-nuclear antibodies, anti-phospholipids antibody, 
anti-INF antibodies and anti-MDA5 antibodies [37]. Further, new clinical reports indi-
cate the presence of autoantibodies which can reach the brain. In patients with severe 
COVID-19 the blood–brain barrier dysfunction was detected as well as the neuronal 
damage was found and increased levels of self-reacting antibodies in cerebrospinal fluid. 
These antibodies mostly recognized the epitopes in the brain. Finally, the fraction of 
patient-derived virus neutralizing monoclonal antibodies can recognize the targets in 
mammalian cells [38]. So far there is no evidence that LCRs may cause the self-reactivity 
of the immune system in other infections but concerning the high number of autoim-
mune side effects after SARS-CoV-2 infection we can not exclude such possibility.
Results
Our aim was to find the LCRs in the SARS-CoV-2 genome that are similar to frag-
ments of human proteins and to identify if any of those overlap with other epitopes in an 
attempt to eliminate epitope hits that are too similar to the human proteome fragments.
Protein similarity between SARS‑CoV‑2 and human LCRs
To achieve this goal we used our three methods: GBSC, MotifLCR and LCR-BLAST. 
GBSC takes as an input whole protein sequences, however the input for LCR-BLAST 
and MotifLCR is expected to consist of LCRs. Therefore to identify LCRs in the SARS-
CoV-2 and in the human proteomes we used the SEG tool with default parameters. The 
detailed description of the data sources and the methods used to identify and analyze 
low complexity regions in SARS-CoV-2 and human proteome is provided in Supplemen-
tal Material 9 “Materials and Methods”. There are 23 LCRs in SARS-CoV-2 proteome 
that were found in the following proteins: nsp2 (636 aa, one LCR found), nsp3 (1945 
aa, six LCRs found) nsp4 (500 aa, one LCR found), nsp6 (290 aa, one LCR found), nsp7 
(83 aa, two LCRs found), nsp8 (198 aa, two LCRs found), S protein (1273 aa, two LCRs 
found), E protein (75 aa, one LCR found), orf7a (121 aa, one LCR found), orf7b (43 aa, 
one LCR found), N protein (419 aa, four LCRs found) and orf14 (73 aa, one LCR found) 
(Fig. 1). It is worth noting that most LCRs are located either in pp1a or in the C-terminal 
proteins (from spike to nucleocapsid protein). The middle section, from nsp9 to nsp16 is 
completely devoid of such sequences. In the next step we identified which of the SARS-
CoV-2 LCRs are similar to human LCRs (Fig. 1). Similar fragments are present in nsp3, 
spike glycoprotein and in the nucleocapsid protein. The list of these regions is presented 
in Table 1. We also provide a list of similar protein fragments from the human proteome 
obtained with three different methods (see Additional files 1, 2, 3: S1-3 Tables).
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Figure  1 SARS-CoV-2 proteins shown according to their encoding position in the 
genome. Low Complexity Regions (LCRs) are marked with triangles. LCRs that are simi-
lar to human proteins are highlighted in red. The original figure for this modification 
was kindly provided by ViralZone, SIB Swiss Institute of Bioinformatics (https:// viral 
zone. expasy. org/ 8996)
Similarity of nsp3 is most significant to the myelin transcription factor 1-like protein 
(Myt1l) (Table 1, Additional files 1, 2, 3: S1-S3 Tables). Myt1l was shown to be expressed 
in neural tissues in the developing mouse embryo [39]. Myt1l is supposed to limit non-
neuronal genes expression, take part in neurogenesis and functional maintenance of 
mature neurons [40]. The glutamic acid-rich fragment is located close to the activation 
domain, however it was shown to be dispensable in this process [41].
The spike glycoprotein fragment MLCCMTSCCSCLKGCCSCGSCC has significant 
similarity to LCRs of ultrahigh sulfur keratin-associated proteins present both in hair 
cortex and cuticle (KRTAP 4.3, KRTAP 5.4 and KRTAP 5.9) [42] (Table  1, Additional 
files 2, 3: S2 and S3 Tables). KRTAPs are parts of the intermediate filaments of the hair 
shaft.
Nucleocapsid protein (N) has 2 LCRs that are similar to human LCRs (Table1, Addi-
tional files 1, 2, 3: S1-S3 Tables) the most interesting comparable fragment is the zinc 
finger Ran-binding domain-containing protein 2 (RANB2), which is a part of the 
supraspliceosome where it is responsible for alternative splicing [43, 44]. GBSC identi-
fies the high similarity of the viral LCR to a LCR of the solute carrier family 12 which 
is an electroneutral potassium-chloride co-transporter which can be mutated in some 
severe peripheral neuropathies [45, 46]. The C-terminal LCR is similar to a LCR from 
[F-actin]-monooxygenase MICAL3, actin-regulatory redox enzyme that directly binds 
and disassembles actin filaments (F-actin) [47]. This protein is also responsible for exo-
cytic vesicles tethering and fusion, and cytokinesis [48–50]. The region of interest is 
probably involved in binding some of a multitude of binding partners of MICAL3 [49] 
(https:// www. ebi. ac. uk/ intact/ inter actors/ id: Q7RTP6*).
Fig. 1 SARS‑CoV‑2 proteins shown according to their encoding position in the genome. Low Complexity 
Regions (LCRs) are marked with triangles. LCRs that are similar to human proteins are highlighted in red. The 
original figure for this modification was kindly provided by ViralZone, SIB Swiss Institute of Bioinformatics 
(https:// viral zone. expasy. org/ 8996)
Table 1 List of SARS‑CoV‑2 low complexity regions that are similar to human proteins
LCR sequence potein LCR start LCR end
PPDEDEEEGDCEEEEFE nsp3 108 124
QPEEEQEEDWLDDDSQ nsp3 152 167
MLCCMTSCCSCLKGCCSCGSCC S protein 1233 1254
GSRGGSQASSRSSSRSRNSSRNSTPGSSRGTSP N protein 175 207
KTFPPTEPKKDKKKKADE N protein 361 378
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Lists of human hits of LCRs similar to viral fragments were annotated with Gene 
Ontology (GO) terms [51] in order to find common functional features that were over-
represented among proteins composing the clusters. Here we focus on the results for 
GO annotations from the Biological Processes namespace since these functions may be 
crucial to understanding possible viral interventions into the cellular machinery. Com-
plete lists of enriched GO terms are available in Additional files 4, 5, 6, 7, 8: Tables S4-S8. 
The best matches for the first LCR in nsp3 are human proteins involved in actin pro-
cessing (Additional files 4: Table S4). The best matches for the adjacent LCR in nsp3 are 
related to signal transduction (Table S5). The best hits for the spike protein LCR frag-
ment are related to keratin (Additional files 6: Table S6). The human proteins similar to 
the central nucleocapsid protein’s LCR show discrepancies between sets of results. The 
output of GBSC clearly points to salinity response/salt stress responses (Additional files 
7: Table S7). Results from LCR-BLAST and MotifLCR are actin-centred (Additional files 
7: Table S7). In the case of the C-terminal nucleocapsid protein LCR, the most abundant 
human representatives are exocytosis and oxidation–reduction processes (Additional 
files 8: Table S8).
Motif similarities of SARS‑CoV‑2 and human LCRs
We also tested similarities of viral LCR fragments to known domains and motifs using 
the UniProt, PROSITE, CDD, InterPro and ELM databases [52–56]. Most of the matches 
to known domains and motifs of the SARS-CoV-2 LCRs are to previously annotated 
regions, i.e. compositionally biased regions, rich in a particular amino acid or polyX 
regions. Only in two cases are there hits to specific domains.
The first similarity between SARS-CoV-2 LCR and a known motif is between the sur-
face glycoprotein LCR (MLCCMTSCCSCLKGCCSCGSCC) and the keratin-associated 
protein domain (IPR002494). By using ScanProsite, we were able to find more than half 
a million of such motifs in the UniProtKB database [57]. Manual inspection of the viral 
LCR fragment shows the presence of a similar C–C–S–C motif. This fragment is also 
present in more than 500,000 sequences in UniProtKB. Interestingly, all 13 hits to the 
human proteome are metallothioneins with very similar motifs that are responsible for 
metal binding [58, 59].
Nsp3 is the largest multi-domain protein encoded by the coronavirus genome. LCR 
of nsp3 (PPDEDEEEGDCEEEEFE) lies across the borders of two domains identified in 
coronaviruses: Ub1 (1-112) and acidic domain hypervariable region (HVR) (113–183) 
[60–62]. This LCR is significantly similar to the Armadillo-type fold (IPR016024), ‘a 
multi-helical fold comprised of two curved layers of alpha helices arranged in a regu-
lar right-handed superhelix, where the repeats that make up this structure are arranged 
about a common axis. These superhelical structures present an extensive solvent-acces-
sible surface that is well suited to binding large substrates such as proteins and nucleic 
acids [63, 64] https:// www. ebi. ac. uk/ inter pro/ entry/ Inter Pro/ IPR01 6024/.
Non‑recommended epitopes of SARS‑CoV‑2
In the last section we investigated the lists of epitopes suggested previously [22]; [16, 65]. 
The authors of those papers provide predictions for 3295 possible candidates for T-cell 
epitopes and 1519 possible candidates for B-cell epitopes. The epitopes for T or B cells 
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may be linear or structural (conformational). Linear epitopes consist of linear amino 
acid (aa) sequence while structural are based on folded protein structure where particu-
lar aa comes close to each other in structure. By analysing this data we found that 21 of 
the predicted T-cell epitopes and 27 (1,7%) of the predicted B-cell epitopes overlap with 
5 SARS-CoV-2 LCRs that are significantly similar to human proteins. However, only the 
S and N proteins from SARS-CoV are known to induce potent and long-lived immune 
responses [66–71]. This narrows the number of potential candidates to 562 (419 for S 
protein and 143 for N protein) for T-cell epitopes and to 397 (317 for S protein and 80 
for N protein) for B-cell epitopes. Among these, we found out that 11 (2%) of the pre-
dicted T-cell epitopes and 19 (5%) of the predicted B-cell epitopes overlap with SARS-
CoV-2 LCRs. The lists of B-cell and T-cell overlapping epitopes are presented in Tables 2 
and 3 respectively and the overlapping fragments are marked in red colour. We therefore 
speculate that these regions should not be taken into account while selecting epitopes.
Discussion
Anti-COVID-19 vaccine development is mainly based on: DNA and RNA technol-
ogy, peptides, virus-like particle, recombinant protein, viral vector, live attenuated 
virus and inactivated virus platforms [72]. Although the epitopes for neutralizing 
SARS-CoV-2 antibody are known, the public information about the specific antigens 
which were used in vaccine development is not available. Some vaccines are based on 
S protein or even on whole virion [73]. Based on our findings in SARS-CoV-2 pro-
teins 5 LCRs common for virus and human proteins are presented, clearly indicating 
that antigens for SARS-CoV-2 vaccine development need to be designed and defined 
with extreme care. In the case of SARS-CoV-2 and other coronaviruses, the develop-
ment of effective vaccine is not trivial. First of all, the proper antigen design is criti-
cal. This may enable avoidance of such side effects of vaccine as autoimmune disease. 
The LCR is known as one of the strongest and most immunogenic epitopes and can 
enhance the immune evasion of pathogen [35]. Additionally, similar LCRs were found 
in the human proteome. Therefore, LCR used as antigen (1) may generate ineffective 
antibody (not blocking virus entry into the cell), and (2) may produce the antibody 
that can serve as the basis for development of autoimmune diseases. Moreover, in 
the case of coronaviruses, the antigen dependent enhancement (ADE) of virus entry 
was observed [74]. Therefore, the harmful antibody developed against the not prop-
erly designed epitope may potentially cause ADE of SARS-CoV-2. In lentivirus and 
HIV-1 the LCRs are potentially hypervariable regions and may contribute to the ret-
roviral ability to avoid the immune system [75]. Thus, in conclusion during the design 
process of the antigen used as the basis for efficient vaccine, the sequences should 
be carefully investigated for the presence of LCRs which may cause potential harm-
ful effects of the produced vaccine. Based on vaccine development against SARS-
CoV and MERS some concerns were recognized including induction of ADE as not 
neutralizing antibody enhanced virus infectivity. ADE was found in cats vaccinated 
against a species-specific coronavirus [76]. In case of SARS, the use of whole inacti-
vated virus or S glycoprotein induced hepatitis and lung immunopathology in animal 
models, while inactivated MERS in vaccination caused pulmonary infiltration in mice 
[77]. Moreover, it is still unclear whether adaptive T cell responses may also play a 
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role in conferring protection against SARS-CoV-2. For SARS-CoV, in human survi-
vors the memory T cells, but not B cells, were found around 6 years after infection 
[78]. The recent study indicated that in COVID-19 patient the 45 various antibodies 
against SARS-CoV-2 were found although only 3 exhibited ability to neutralize the 
Table 2 SARS‑CoV‑2 low complexity regions that overlap with B‑cell epitopes










* S MVTIMLCCMTS MLCCMTSCCSCLKGCCSCG
SCC 















160 181 175 207 32%
** N PKGFYAEGSRGGSQASSR GSRGGSQASSRSSSRSRNS
SRNSTPGSSRGTSP
168 185 175 207 61% 
** N SRGGSQASSRSSSRSR GSRGGSQASSRSSSRSRNS
SRNSTPGSSRGTSP
176 191 175 207 100% 
** N KHIDAYKTFPPTEPKKDKK
K 
KTFPPTEPKKDKKKKADE 355 375 361 378 67%
** N LNKHIDAYKTFPPTEPK KTFPPTEPKKDKKKKADE 353 369 361 378 43%
** N KTFPPTEPKKDKKKK KTFPPTEPKKDKKKKADE 361 375 361 378 100%
** N TFPPTEPK KTFPPTEPKKDKKKKADE 362 369 361 378 100%














QPEEEQEEDWLDDDSQ 109 217 152 167 15%
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virus [79]. Additionally, antibody against SARS-CoV-2 may cause the cross-reactivity 
with pulmonary surfactant proteins (shared similarity with 13 out of 24 pentapep-
tides) and development of SARS-CoV-2-associated lung disease [80]. Furthermore, 
recent study indicated that antibody against S glycoprotein exhibited ability to cross-
react with human tissue proteins including: S100B, transglutaminase 3 and 2 (tTG3, 
tTG2), myelin basic protein (MBP), nuclear antigen (NA), αmyosin, collagen, claudin 
5 + 6 and thyroid peroxidase (TPO) [81].
Our work clearly shows similarity of SARS-CoV-2 protein low complexity sequences 
to human LCRs. We were able to detect similarity in 3 SARS-CoV-2 proteins to sev-
eral human protein families. This resemblance can be seen in the nsp3, spike protein 
(S) as well as in the nucleocapsid protein (N). Previous research shows that both S 
Table 2 (continued)
*** nsp3 GDCEEEEFEP PPDEDEEEGDCEEEEFE 116 125 108 124 90%
*** nsp3 EEFEPSTQYE PPDEDEEEGDCEEEEFE 121 130 108 124 40% 
*** nsp3 EEFEPSTQY PPDEDEEEGDCEEEEFE 121 129 108 124 43%
*** nsp3 AALQPEEEQE QPEEEQEEDWLDDDSQ 148 157 152 167 70% 











166 215 175 207 66%
*** N GFYAEGSRGG GSRGGSQASSRSSSRSRNSS
RNSTPGSSRGTSP
170 179 175 207 60%
*** N GGSQASSRSS GSRGGSQASSRSSSRSRNSS
RNSTPGSSRGTSP
178 187 175 207 100%
*** N ASSRSSSRSR GSRGGSQASSRSSSRSRNSS
RNSTPGSSRGTSP
182 191 175 207 100%
*** N RNSSRNSTPG GSRGGSQASSRSSSRSRNSS
RNSTPGSSRGTSP
191 200 175 207 100% 
*** N TPGSSRGTSP GSRGGSQASSRSSSRSRNSS
RNSTPGSSRGTSP
198 207 175 207 100%
*** N GTSPARMAGN GSRGGSQASSRSSSRSRNSS
RNSTPGSSRGTSP




KTFPPTEPKKDKKKKADE 358 415 361 378 26%
* —epitopes derived from [22], **—epitopes derived from [16], ***—epitopes derived from[65]
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Table 3 SARS‑CoV‑2 low complexity regions that overlap with T‑cell epitopes








% of coverage 
* nsp3  GDCEEEEFEPSTQY PPDEDEEEGDCEEEEFE 116 129 108 124 64% 
* N AYKTFPPTEPK KTFPPTEPKKDKKKKADE 359 369 361 378 82%
** S CMTSCCSCLK MLCCMTSCCSCLKGCCSCGSCC 1236 1245 1233 1254 100%
** S MTSCCSCLK MLCCMTSCCSCLKGCCSCGSCC 1237 1245 1233 1254 100%
** N LLNKHIDAYKTFPPTEPK KTFPPTEPKKDKKKKADE 352 369 361 378 50%
** N YKTFPPTEPKKDKKKK KTFPPTEPKKDKKKKADE 360 375 361 378 94%
** N SQASSRSSSR GSRGGSQASSRSSSRSRNSSRN
STPGSSRGTSP
180 189 175 207 100%
** N AEGSRGGSQA GSRGGSQASSRSSSRSRNSSRN
STPGSSRGTSP
173 182 175 207 80% 
** N IDAYKTFPPTEPKKD KTFPPTEPKKDKKKKADE 357 371 361 378 69% 
** N NKHIDAYKTFPPTEP KTFPPTEPKKDKKKKADE 354 368 361 378 53% 
** N KTFPPTEPKK KTFPPTEPKKDKKKKADE 361 370 361 378 100% 
** N KTFPPTEPK KTFPPTEPKKDKKKKADE 361 369 361 378 100%
*** nsp3 EEFEPSTQY PPDEDEEEGDCEEEEFE 121 129 108 124 43% 
*** nsp3 YAEGSRGGSQASSRS GSRGGSQASSRSSSRSRNSSRNS
TPGSSRGTSP
172 186 175 207 80%
*** nsp3 RSRNSSRNS GSRGGSQASSRSSSRSRNSSRNS
TPGSSRGTSP
185 194 175 207 100%
*** nsp3 SSRSRNSSR GSRGGSQASSRSSSRSRNSSRNS
TPGSSRGTSP
187 195 175 207 100%
*** nsp3 SSRSSSRSR GSRGGSQASSRSSSRSRNSSRNS
TPGSSRGTSP
183 191 175 207 100% 
*** nsp3 SSRNSTPGS GSRGGSQASSRSSSRSRNSSRNS
TPGSSRGTSP
193 198 175 207 100%
*** nsp3 QASSRSSSR GSRGGSQASSRSSSRSRNSSRNS
TPGSSRGTSP
181 189 175 207 100% 
*** nsp3 SSRGTSPAR GSRGGSQASSRSSSRSRNSSRNS
TPGSSRGTSP
201 209 175 207 78% 
*** nsp3 KTFPPTEPK KTFPPTEPKKDKKKKADE 361 369 361 378 100%
* —epitopes derived from [22], **—epitopes derived from [16], ***—epitopes derived from [65]. Red colour represents 
exact matches, orange colour represents encompassing matches and violet colour represents overlapping matches
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and N proteins are known to induce potent and long-lived immune responses against 
SARS-CoV.
The nsp3 LCR fragments are part of the hypervariable region (HVR) which is Glu-
rich. This region, even if so variable, is always present in all Coronoviridae. It is known 
to interact with nsp6, nsp8, nsp9 and its own C-terminal part, however no function has 
been assigned to it to date [61, 82]. The same is true for the human transcription factor 
Myt1l’s glutamic acid-rich region which has an unknown role. Of note is the fact that 
the enrichment of glutamic acid was found as a feature of the highly immunogenic poly-
peptides [35]. Since Mytl1l is a transcription factor we may hypothesize that its LCR is 
somehow linked to the general function of binding nucleic acids. Such parallels may be 
helpful in understanding SARS-CoV-2 processes.
The surface glycoprotein (S) is of utmost interest to the scientific and medical com-
munities because of its presence on the viral particle surface. The LCR identified in 
this study is a part of the cysteine-rich motif (CRM) present in the S2 domain, in the 
most C-terminal end of the protein located in the cytoplasm (endodomain) [83]. This 
sequence has been shown to be palmitoylated which is a critical step towards incorpora-
tion of S to the viral envelope [84–91]. Similarities to keratin-associated proteins and 
metallothioneins are hard to interpret. There are many possible explanations. One of 
them is the presence in epithelium. The function of this set of cysteines demands a more 
detailed study. Buonvino and Melino suggest a hypothetic active role of the coronavirus 
S protein cytoplasmic domain in protein–protein aggregation for clots formation and 
cell–cell fusion SARS-CoV-2-S protein-driven [92].
The nucleoprotein/nucleocapsid phosphoprotein (N) packages the viral genome into 
a helical ribonucleocapsid (RNP) and is crucial during viral self-assembly as shown in 
experiments with previously known coronaviruses [93–98]. Both regions of interest 
are located in the SR-rich region of the linkage region (LKR: residues 176–204) and the 
C-terminal disordered region (residues 370–389) that together with the N-terminal part 
are involved in RNA binding [99, 100]. Similarity of the N protein to RANB2, an element 
of the supraspliceosome, seems surprising. However a hypothesis based on results from 
zebrafish may point at RANB2 as a weapon against infections, as is the case of the fish 
ZRANB2 [101]. The C-terminal LCR is similar to the human MICAL3 LCR which is 
multifunctional [48, 49]. Gene Ontology analyses studies appear to indicate an intrigu-
ing over-representation of transport functions among human proteins whose LCRs are 
similar to coronavirus proteins.
It is known that viruses attack major cellular processes like vesicular trafficking, cell 
cycle, cellular transport, protein degradation and signal transduction to realize their 
goals [102]. Many host processes are taken over by viral proteins with the use of short 
linear motifs that are often parts of intrinsically disordered regions (IDRs). For example, 
the RGD motif mimics the regular cellular machinery for cell attachment via integrin 
[103]. Many IDRs are composed of low complexity regions. Therefore the hypothesis of 
the importance of similarities described above are not unfounded. Thorough analysis 
of SARS-CoV-2 short linear motifs has been recently published by the Gibson’s group 
[104].
The most important outcome of this work is the indication that epitopes cannot 
be selected based only on factors like phylogenetic conservation or potential epitope 
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targets. For the safety of patients and procedures, all epitopes that may be similar to 
human proteome fragments should be discarded from further studies because the 
cure against SARS-CoV-2 may as well turn against the host.
Due to the fact that several research groups are working on the development of 
vaccine against SARS-CoV-2 it is very important to highlight the possible weak 
points which may cause unexpected side effects. The autoimmune diseases rate 
increased significantly in recent years. Moreover, it correlates with vaccination pro-
grammes [105]. Several studies indicated that vaccine components may induce auto-
immune disease e.g. vaccine against Lyme disease can cause chronic arthritis and 
rheumatic heart disease [106]. However the mechanism triggering autoimmune dis-
ease after vaccination still remains unclear [107].
We also note a complete lack of LCRs in proteins originating from the nsp9-nsp16 
proteins (Fig. 1). Previous studies have shown that LCRs are more often present on 
protein ends [108], which are hard to define in polyproteins as in the case of pp1ab. 
The only distinguishing feature of these proteins is their function; most proteins 
from this group are involved in replication [109]. We speculate that the similarity of 
viral LCRs to human proteins may not be purely accidental but may be a molecular 
disguise. We suggest that SARS-CoV-2 may use these regions for specific functions 
that replace the cellular machinery for its own purposes.
Here we provide the scientific community with tools that allow the comparison of 
all types of low complexity fragments. These techniques have been shown to be use-
ful previously in order to detect previously unknown similarities (Kubáň et al., 2019; 
Tørresen et al., 2019) and based on previous results we decided to use these tools to 
search for similarities among human and SARS-CoV-2 low complexity regions.
LCRs appear to come in 3 flavours. They can consist of homogenous polyX regions 
(homorepeats), repetitive fragments, or irregular LCRs [110]. Secondly, they usu-
ally come in specific combinations of amino acids, e.g. hydrophobic, cysteine-rich 
(alone or in combination with histidines), and glutamic acid always goes with aspar-
tic acid. Our methods are tailored to detect the different types of such low complex-
ity regions.
The reader of this work should be aware that our results are based on sequence 
similarity only. We are fully aware that we do not include possible topological simi-
larities of epitopes. These structural resemblances may of course play a role in com-
parison of even phylogenetically and fold-wise distant protein structures, as shown 
in allergic cross-reactivity [111, 112]. We therefore cannot exclude that other simi-
larities exist between SARS-CoV-2 and human proteins that are not identified here.
Conclusions
Finding of five low complexity regions (LCRs) in three SARS-CoV-2 encoded pro-
teins (nsp3, S and N) that are highly similar to regions from human proteome poses 
a serious threat to the vaccine or drug design. Similarity of SARS-CoV-2 LCRs to 
human proteins may have implications on the ability of the virus to counteract 
immune defense. The vaccine targeting LCRs may potentially be ineffective or alter-
natively lead to autoimmune diseases development.
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Methods
SARS‑CoV‑2 protein sequences
All full-length protein sequences of the SARS-CoV-2 proteome were retrieved on 28 
April 2020 from the ViralZone web portal (https:// viral zone. expasy. org/ 8996) which pro-
vides pre-release access to the SARS Coronavirus 2 protein sequences in UniProt. The 
UniProtIDs of the SARS-CoV-2 proteins are P0DTC1 replicase polyprotein 1a (pp1a), 
P0DTD1 Replicase polyprotein 1ab (pp1ab), P0DTC2 Spike glycoprotein (S), P0DTC3 
ORF3a protein (NS3a), P0DTC4 Envelope small membrane protein (E), P0DTC5 Mem-
brane protein (M), P0DTC6 ORF6 protein, P0DTC7 ORF7a protein, P0DTD8 ORF7b 
protein, P0DTC8 ORF8 protein, P0DTC9 Nucleoprotein (N), P0DTD2 ORF9b protein, 
P0DTD3 ORF14 protein and A0A663DJA2 hypothetical ORF10 protein. Based on the 
information derived from UniProt replicase polyprotein 1a and replicase polyprotein 
1ab were then divided into proteinases responsible for the cleavages of the polypro-
teins, that is: nsp1, nsp2, nsp3, nsp4, 3C-like proteinase, nsp6, nsp7, nsp8, nsp9, nsp10, 
nsp11, RNA-directed RNA polymerase, helicase, proofreading exoribonuclease and 2-O 
methyltransferase.
Identification of LCRs
To identify low complexity fragments in SARS-CoV-2 proteins we used the PlatoLoCo 
metaserver [31] which provides a web interface to a set of state-of-the-art methods that 
allow detection of LCRs, compositionally biased protein fragments, and short tandem 
repeats. Using all these methods we were only able to detect low complexity protein 
fragments using the SEG algorithm using the default parameters (W = 12, K 1 = 2.2, K 
2 = 2.5). To identify low complexity protein fragments in the human genome we down-
loaded human proteome from the Uniprot database (UP000005640) and analysed it 
using SEG with the same set of parameters.
Having LCRs identified based on the proteins derived from the reference SARS-CoV-2 
genome we have also analysed the number of mutations already discovered for each AA 
position in the regions of our interest in order to check if those regions are characterized 
by a high mutation rate. To perform such analysis we downloaded mutation data from 
the COVIDep [113], 114. As for the date of data accession (January 8th, 2021) COV-
IDep database included 232,735 analysed SARS-CoV-2 sequences and CoV-GLUE data-
base included 242,865 SARS-CoV-2 sequences. Based on the obtained information we 
computed the percentage of the sequences with mutations for each residue of detected 
LCRs. We notice that for most of the residues the number of sequences with mutations 
is below 1%. The only exceptions are residues 194, 199, 203, 204 and 365, 376, 377 from 
two LCR fragments from nucleoprotein (N) where mutation percentages are 5,8%, 3%, 
33,6%, 33,6%, and 1.7%, 2,6%, 1,4% in case of the COVIDep database, and 5,2%, 1,7%, 
36,9%, 36,8%, and 1,2%, 1,7%, 1% in case of the CoV-GLUE database, respectively. How-
ever, due to way greater resistance of LCRs to mutations this kind of change does not 
seem to be crucial for their functions [115, 116].
The detailed information of the percentage of sequences with mutations from the 
COVIDep and the CoV-GLUE databases for each residue of detected SARS-CoV-2 LCRs 
is provided in the Supplementary Material S9.
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Searching for human protein fragments similar to SARS‑CoV‑2 LCRs
To detect human sequences that are similar to SARS-CoV-2 LCRs we used our three 
methods: GBSC, MotifLCR and LCR-BLAST (e-value threshold 0.001). The list of 
human LCRs that are similar to virus LCRs obtained with GBSC, MotifLCR and LCR-
BLAST are presented in a Additional files 1, 2, 3: tables S1, S2 and S3, respectively. For 
GBSC we used default parameters (score threshold 3, distance threshold 7). The method 
uses whole protein sequences as an input and then identifies repetitive regions that con-
sistof homopolymers or STRs. Then, similar protein fragments are clustered together 
and each cluster represents particular repetitive patterns. As a result we obtained two 
clusters that included both virus and human sequences. MotifLCR and LCR-BLAST 
require low complexity fragments as input. In our case these sequences were obtained 
using the SEG tool as described above. In the first step MotifLCR removes unique 2-mers 
in each sequence in order to create artificial sequences, then it searches for repeats in 
these new sequences and in the last step it creates clusters with native sequences that 
contain tandem repeats in artificial sequences. Repeat is defined as at least 3 times the 
occurrence of a specific amino acid pattern.
MotifLCR results consisted of 20 clusters that represented different repetitive motifs. 
However, the repetitive motifs in the obtained clusters were not specific. Therefore to 
further narrow down the sequences we used the results of MotifLCR as a subject data-
base for LCR-BLAST and a list of viral LCRs as a query set. Finally, as a third tool we 
used LCR-BLAST with the viral LCRs as a query set and all human proteome LCRs as 
a subject database. As a result both MotifLCR and LCR-BLAST returned five clusters 
each with human LCRs sequences similar to SARS-CoV-2 LCRs.
Comparing SARS‑CoV‑2 LCRs to epitopes
Having selected virus fragments that are similar to human sequences we then investi-
gated the lists of T-cell and B-cell epitopes suggested by [22]; [16, 61] in their works. The 
authors of the first work provide beginning and end amino acid coordinates for each 
epitope as well as a name of the virus protein and based on this information we were 
able to identify epitope regions that overlap with SARS-CoV-2 LCRs. In case of the list 
of epitopes provided by [16] and [61] we used WU-BLAST (http:// blast. wustl. edu) with 
no gaps and parameters optimized for short sequences to find epitopes that align with 
100% identity to SARS-CoV-2 LCRs and threshold of minimum length of aligned frag-
ment of 4AA (Additional files 9, 10).
Gene Ontology enrichment
Gene Ontology enrichment functional analyses were performed on 12 clusters that 
included sequences similar to SARS-CoV-2 LCRs. Since some proteins may contain 
more than one LCR, and each of these LCRs may appear in the cluster, in order to 
avoid redundancy, enrichment analyses have been performed on lists of unique protein 
sequences. Reference sets for statistical analyses were created depending on the method 
used to generate clusters. In the case of GBSC to create a reference set we used all 11,361 
unique human proteins that composed all other clusters found by the method. In the 
case of MotfLCR as well as in the case of LCR-BLAST we used the same protein sets that 
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were used to create bastp search databases and the sizes of the reference sets were 33,880 
and 45,068 proteins respectively. To annotate human proteins with their corresponding 
GO terms from Biological Process, Molecular Function and Cellular Component names-
paces we used BiomaRt R package [102]. Statistical analysis was performed with topGO 
R package [103] and to assess overrepresentation of GO term annotations in obtained 
clusters we applied hypergeometric test with false discovery Benjamin-Hochberg multi-
ple testing correction with adjusted p-value cutoff 5%.
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